dose of drugs that are CYP2D6 substrates as necessary.fenfluramineMonitor Closely (3)fenfluramine, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. desipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. desipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)desipramine, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.fesoterodineMinor (1)fesoterodine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.fexinidazoleSerious - Use Alternative (1)fexinidazole and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.fingolimodMonitor Closely (1)fingolimod and desipramine both increase QTc interval. Use Caution/Monitor.flavoxateMinor (1)flavoxate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.flecainideMonitor Closely (1)desipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluconazoleSerious - Use Alternative (1)desipramine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.fluoxetineMonitor Closely (1)desipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (2)fluoxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluphenazineMonitor Closely (1)fluphenazine and desipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)fluphenazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)desipramine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. desipramine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.flurazepamMonitor Closely (1)flurazepam and desipramine both increase sedation. Use Caution/Monitor.fluvoxamineMonitor Closely (1)fluvoxamine and desipramine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.formoterolMonitor Closely (1)desipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)desipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug. desipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.fosamprenavirSerious - Use Alternative (1)fosamprenavir increases levels of desipramine by decreasing metabolism. Avoid or Use Alternate Drug.foscarnetMonitor Closely (1)desipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fostemsavirMonitor Closely (1)desipramine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. frovatriptanMonitor Closely (1)frovatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentinMonitor Closely (1)gabapentin, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilMonitor Closely (1)gabapentin enacarbil, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantamineMinor (1)galantamine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.ganaxoloneMonitor Closely (1)desipramine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMonitor Closely (1)gemifloxacin and desipramine both increase QTc interval. Use Caution/Monitor.gilteritinibMonitor Closely (1)gilteritinib and desipramine both increase QTc interval. Use Caution/Monitor.givosiranSerious - Use Alternative (1)givosiran will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glimepirideMinor (1)desipramine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizideMinor (1)desipramine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburideMinor (1)desipramine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.glycopyrrolateMonitor Closely (1)desipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.Minor (1)glycopyrrolate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.glycopyrrolate inhaledMonitor Closely (1)desipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.Minor (1)glycopyrrolate inhaled and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, desipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.goserelinMonitor Closely (1)desipramine and goserelin both increase QTc interval. Use Caution/Monitor.granisetronSerious - Use Alternative (2)granisetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. granisetron and desipramine both increase QTc interval. Avoid or Use Alternate Drug.guanfacineSerious - Use Alternative (1)desipramine decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.haloperidolMonitor Closely (1)haloperidol and desipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)desipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. haloperidol will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.henbaneMonitor Closely (1)henbane and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropineMonitor Closely (1)homatropine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodoneMonitor Closely (1)hydrocodone, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphoneMonitor Closely (1)hydromorphone and desipramine both increase sedation. Use Caution/Monitor.hydroxychloroquine sulfateSerious - Use Alternative (1)hydroxychloroquine sulfate and desipramine both increase QTc interval. Avoid or Use Alternate Drug.hydroxyprogesterone caproate (DSC)Minor (1)hydroxyprogesterone caproate (DSC), desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.hydroxyzineMonitor Closely (2)hydroxyzine and desipramine both increase sedation. Use Caution/Monitor. hydroxyzine and desipramine both increase QTc interval. Use Caution/Monitor.hyoscyamineMonitor Closely (1)hyoscyamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)hyoscyamine spray and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ibrutinibMonitor Closely (1)desipramine increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib.ibutilideContraindicated (1)desipramine and ibutilide both increase QTc interval. Contraindicated.iloperidoneMonitor Closely (2)desipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely. iloperidone and desipramine both increase sedation. Use Caution/Monitor.imatinibMonitor Closely (2)imatinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. desipramine will increase the level or effect of imatinib by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.imipramineMonitor Closely (2)desipramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. desipramine and imipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)desipramine and imipramine both increase QTc interval. Avoid or Use Alternate Drug. desipramine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.indacaterol, inhaledMonitor Closely (1)indacaterol, inhaled, desipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.indapamideContraindicated (1)desipramine and indapamide both increase QTc interval. Contraindicated.insulin aspartMinor (1)desipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirMinor (1)desipramine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glargineMinor (1)desipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisineMinor (1)desipramine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisproMinor (1)desipramine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHMinor (1)desipramine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humanMinor (1)desipramine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.iobenguane I 123Contraindicated (1)desipramine decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.iobenguane I 131Serious - Use Alternative (1)desipramine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.ipratropiumMonitor Closely (1)ipratropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isocarboxazidContraindicated (1)isocarboxazid and desipramine both increase serotonin levels. Contraindicated.isofluraneMonitor Closely (1)isoflurane and desipramine both increase QTc interval. Use Caution/Monitor.isoniazidMonitor Closely (1)desipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenolMonitor Closely (1)desipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)desipramine, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.Minor (1)isoproterenol, desipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.itraconazoleMonitor Closely (1)itraconazole and desipramine both increase QTc interval. Use Caution/Monitor.ivosidenibSerious - Use Alternative (1)ivosidenib and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.ketamineMonitor Closely (1)ketamine and desipramine both increase sedation. Use Caution/Monitor.Minor (1)ketamine, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.ketoconazoleSerious - Use Alternative (1)desipramine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.ketotifen, ophthalmicMonitor Closely (1)desipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophanMonitor Closely (1)desipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibMonitor Closely (1)desipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanMonitor Closely (2)lasmiditan, desipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions. desipramine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome.lefamulinSerious - Use Alternative (1)lefamulin and desipramine both increase QTc interval. Avoid or Use Alternate Drug.lemborexantMonitor Closely (1)lemborexant, desipramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuterolMonitor Closely (1)desipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)desipramine, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.levofloxacinMonitor Closely (1)desipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levoketoconazoleSerious - Use Alternative (1)desipramine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.levomilnacipranSerious - Use Alternative (1)levomilnacipran and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.levorphanolMonitor Closely (1)levorphanol and desipramine both increase sedation. Use Caution/Monitor.levothyroxineMonitor Closely (1)levothyroxine increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.linezolidSerious - Use Alternative (1)linezolid and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.liothyronineMonitor Closely (1)liothyronine increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.liotrixMonitor Closely (1)liotrix increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.lisdexamfetamineMonitor Closely (2)desipramine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s). desipramine increases